Ask AI
ProCE Banner Series

Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients

Learning Objectives

•    Review FL disease state and unmet needs
•    Examine the study design and efficacy of MONJUVI+ R2, a CD19 and CD20-targeted immunotherapy combination
•    Cover safety and dosing of MONJUVI + R2

All Events

Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients

Upcoming Events

March

04

2026

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Additional Info

Acknowledgement

Sponsored By

Incyte